CYTOKINETICS INC
CYTKdata completeness 100%27 fiscal years on fileCYTOKINETICS INC earns about -88% on equity, but has diluted owners by 56% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $70.4M1 | $94.6M2 | $7.53M3 | $18.5M3 | $88M3 |
| Net income | −$215.3M4 | −$389M5 | −$526.2M6 | −$589.5M6 | −$785M6 |
| Operating cash flow | −$142.5M7 | −$299.5M8 | −$414.3M9 | −$395.9M9 | −$510M9 |
| Capital expenditure | $48.9M10 | $11.3M11 | $1.42M12 | $3.91M12 | $24.8M12 |
| Free cash flow (derived) | −$191.4M7 | −$310.9M8 | −$415.7M9 | −$399.8M9 | −$534.8M9 |
| Total debt | $47.4M13 | $714.3M14 | $707.7M15 | $724.3M16 | $287.6M16 |
| Cash & equivalents | $112.7M17 | $65.6M18 | $113M19 | $94.9M20 | $122.5M20 |
| Diluted shares | 76,886 | 89,825 | 96,524 | 111,979 | 120,103 |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on −$54,921.61 of net worth that earned you −$65,356.82 and generated −$44,529.78 of cash last year, against $23,943.2 of debt.
It earned an average -88% on equity over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 56% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has risen 507% over the same window.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0000950170-24-022256 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-029206 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001193125-26-076495 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0000950170-24-022256 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-029206 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001193125-26-076495 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0000950170-24-022256 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-029206 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001193125-26-076495 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0000950170-24-022256 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-029206 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001193125-26-076495 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0000950170-23-005515 (LongTermDebtNoncurrent)
- 10-K · period ending 2022-12-31 · accession 0000950170-24-022256 (LongTermDebtNoncurrent)
- 10-K · period ending 2023-12-31 · accession 0000950170-25-029206 (LongTermDebtNoncurrent)
- 10-K · period ending 2024-12-31 · accession 0001193125-26-076495 (LongTermDebtNoncurrent)
- 10-K · period ending 2021-12-31 · accession 0000950170-23-005515 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0000950170-24-022256 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0000950170-25-029206 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001193125-26-076495 (CashAndCashEquivalentsAtCarryingValue)